Renal denervation in the real-world: performance in high risk subgroups

Sponsored by Medtronic

Summary

After having evoked in particular the SPRAL HTN Global Clinical Program, the RDN consensus statements, the EHS position paper 2021, the ARDeC, and the STEP Trial, Tzung-Dau Wang shares his experience in using renal denervation to manage uncontrolled hypertension by illustrating his words with the case of a 42-year-old male patient with uncontrolled hypertension...